EGFR/HER3 ADC: Phase 1 Esophageal Cancer Trial
## Pharmacokinetics, Immunogenicity, and Biomarker Analysis of BL-B01D1: A First-in-Human Study
### Introduction
This report details the pharmacokinetic (PK) profile, immunogenicity, and exploratory biomarker analyses from a first-in-human study of BL-B01D1, an innovative antibody-drug conjugate (ADC) designed for targeted cancer therapy. Understanding these aspects is crucial for optimizing treatment strategies and predicting clinical outcomes. We present findings related to drug exposure, the body’s immune response to the treatment, and the correlation between biomarker expression and antitumor activity.
### Pharmacokinetics of BL-B01D1
The pharmacokinetic behavior of BL-B01D1 was thoroughly investigated across a range of doses. Results indicate a dose-proportional increase in the maximum concentration (Cmax) of total antibody (TAB), the ADC itself, and the released toxin (Ed04). this suggests predictable drug exposure with increasing dosage.Importantly, the time to reach maximum concentration (Tmax) for TAB, ADC, and the toxin remained consistent between the dose groups studied, indicating a stable absorption and distribution pattern.
The half-life (T1/2) of BL-B01D1 demonstrated a range of 19.9 to 21.9 hours across doses of 2.0 mg/kg to 2.5 mg/kg following a single management. This relatively long half-life is a promising characteristic, possibly allowing for less frequent dosing schedules. Further PK parameters, including the area under the blood concentration-time curve from 0 to infinity (AUC0-∞) and to the last detectable concentration collection time t (AUC0-t), clearance, terminal elimination rate (lambda (λz)), and volume of distribution (Vd) are comprehensively summarized in Supplementary Table 3.These detailed PK data provide a robust foundation for future dose optimization and clinical trial design.
### Immunogenicity Assessment
While the immunogenicity data were immature at the time of analysis, ongoing monitoring is essential. The advancement of anti-drug antibodies (ADAs) can potentially impact drug efficacy and safety, and continued assessment will provide valuable insights into the long-term immunological response to BL-B01D1.We are committed to providing a comprehensive immunogenicity profile as more data become available.
### Biomarker Analysis: EGFR and HER3 expression
To explore potential predictive biomarkers for response to BL-B01D1, we conducted exploratory analyses of EGFR and HER3 expression levels in tumor tissue samples. Tumor specimens were collected whenever feasible and analyzed using immunohistochemistry (IHC). In the 2.5 mg/kg dose group, tumor samples were available for 50 out of 60 patients, with 44 cases deemed suitable for efficacy evaluation. the remaining ten patients’ samples either lacked sufficient tumor tissue sections for IHC staining or exhibited inadequate tumor cellularity upon pathology review.
Interestingly, nearly all tumors evaluated expressed both EGFR and HER3, regardless of pretreatment status. However, our analysis did *not* reveal a discernible correlation between EGFR or HER3 expression levels and antitumor response (Extended Data Fig. 5). This suggests that, at least in this study, EGFR and HER3 expression alone may not be reliable predictors of clinical benefit from BL-B01D1.
Detailed information regarding sample availability, biomarker evaluation methodologies, and comparative subgroup analyses can be found in the Methods section and Supplementary Tables 4 and 5. Further examination into option or combinatorial biomarker strategies is ongoing to identify potential predictors of response and personalize treatment approaches.